Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial

Rivaroxaban Versus Enoxaparin for Thromboprophylaxis After major Gynecological Cancer Surgery: The VALERIA Trial

Direct oral anticoagulants (DOACs) for venous thromboembolism (VTE) prevention after major gynecological cancer surgery might be an alternative to parenteral low-molecular-weight heparin (LMWH). Patients undergoing major gynecological cancer surgery were randomized at hospital discharge to receive r...

Full description

Bibliographic Details
Main Authors: André Luiz Malavasi Longo de Oliveira MD, MSc, Renata Fernanda de Oliveira Pereira MD, Leandro Barile Agati Ph.D, Camilla Moreira Ribeiro Ph.D, Gabrielly Yukimi Kawamura Suguiura, Claudia Helena Cioni MD, Marilsa Bermudez MD, Márcia Bermudez Pirani MD, Roberto Augusto Caffaro MD, Ph.D, Valter Castelli, Valéria Cristina Resende Aguiar MD, Giuliano Giova Volpiani MD, Adilson Paschoa MD, Ph.D, Ariane Vieira Scarlatelli Macedo MD, Pedro Gabriel Melo de Barros e Silva MD, Ph.D, João Carlos de Campos Guerra MD, Ph.D, Jawed Fareed Ph.D, Renato Delascio Lopes MD, Ph.D, Eduardo Ramacciotti MD, Ph.D
Format: Article
Language:English
Published: SAGE Publishing 2022-12-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/10760296221132556

Internet

https://doi.org/10.1177/10760296221132556

Similar Items